Shares of IDEXX Laboratories (IDXX) are skyrocketing in pre-market trading on Monday, surging 22.54% following the company's impressive second-quarter 2025 results and upgraded full-year guidance. The veterinary diagnostics leader has significantly outperformed market expectations, showcasing robust growth across its business segments.

IDEXX reported second-quarter earnings per share (EPS) of $3.63, substantially beating the FactSet analyst estimate of $3.30. Revenue for the quarter reached $1.109 billion, surpassing the expected $1.067 billion. The company's performance was primarily driven by strong growth in its Companion Animal Group (CAG) segment, with CAG Diagnostics recurring revenue increasing by 9% as reported and 7% organically. Notably, IDEXX saw a remarkable 66% growth in CAG Diagnostics instrument revenues, bolstered by the success of recent innovations like the IDEXX InVue Dx™ and IDEXX Cancer Dx™.

In light of these strong results, IDEXX has raised its full-year 2025 guidance. The company now expects revenue in the range of $4.205 billion to $4.280 billion, reflecting a growth of 7.7% to 9.7%. Additionally, IDEXX increased its EPS guidance to a range of $12.40 to $12.76, up from the prior projection of $11.93 to $12.43. This improved outlook, coupled with the company's solid Q2 performance and continued innovation in pet diagnostics, has clearly resonated with investors, driving the significant stock surge in pre-market trading.